Drug treatment and cost of cardiovascular disease in Australia

QR Code

Drug treatment and cost of cardiovascular disease in Australia

Australia's Pharmaceutical Benefits Scheme supports the use of effective drugs for the prevention and control of cardiovascular risk factors. However, there are little data available describing per person costs of medication in primary prevention and secondary prevention in the community. We ai...

Full description

Bibliographic Details
Main Authors:	Ademi, Z., Liew, D., Chew, D., Conner, G., Shiel, L., Nelson, M., Soman, A., Steg, G., Bhatt, D., Reid, Christopher
Format:	Journal Article
Published:	Wiley-Blackwell Publishing Ltd. 2009
Online Access:	http://hdl.handle.net/20.500.11937/2864

Similar Items

Outcomes and excess costs among patients with cardiovascular disease
by: Ademi, Z., et al.
Published: (2013)

Prevalence and Outcomes of Undiagnosed Peripheral Arterial Disease Among High Risk Patients in Australia: An Australian REACH Sub-Study
by: Si, Si, et al.
Published: (2018)

Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry
by: Ademi, Z., et al.
Published: (2011)

Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort
by: Ademi, Z., et al.
Published: (2013)

Australians at Risk: Management of Cardiovascular Risk Factors in the REACH Registry
by: Reid, Christopher, et al.
Published: (2008)

The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-Year follow-up data from the australian REACH registry
by: Ademi, Z., et al.
Published: (2013)

Predictors of health care use among patients with or at high risk of atherothrombotic disease: Two-year follow-up data
by: Ademi, Z., et al.
Published: (2014)

Outcomes from the REACH registry for Australian general practice patients with or at high risk of atherothrombosis
by: Reid, Christopher, et al.
Published: (2012)

Economic implications of obesity among people with atherothrombotic disease
by: Ademi, Z., et al.
Published: (2010)

Cardiovascular disease in Australia: Calm before a new storm?
by: Reid, Christopher
Published: (2013)

An international model to predict recurrent cardiovascular disease
by: Wilson, P., et al.
Published: (2012)

Update on trials examining effects of night-time blood pressure lowering drug treatment on prevention of cardiovascular disease
by: Ho, Chau Le Bao, et al.
Published: (2022)

A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era
by: Ariyaratne, T., et al.
Published: (2016)

Epidemiology of cardiovascular disease
by: Reid, Christopher, et al.
Published: (2016)

Prevention of Cardiovascular Disease
by: Owen, A., et al.
Published: (2012)

Androgens And Cardiovascular Disease In Men
by: Yeap, B., et al.
Published: (2019)

Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms
by: Zomer, E., et al.
Published: (2014)

The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: Best case scenario analysis using a Markov model
by: Zomer, E., et al.
Published: (2012)

Risk factor management in a contemporary Australian population at increased cardiovascular disease risk
by: Campbell, D., et al.
Published: (2018)

Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study
by: Ho, C., et al.
Published: (2018)

Cardiovascular readmissions and excess costs following percutaneous coronary intervention in patients with chronic kidney disease: Data from a large multi-centre Australian registry
by: Ariyaratne, T., et al.
Published: (2013)

Statins for people at low risk of cardiovascular disease: Authors' reply
by: Zomer, E., et al.
Published: (2012)

Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis
by: De Courten, B., et al.
Published: (2008)

Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective
by: Zomer, E., et al.
Published: (2018)

Predicting the impact of polypill use in a metabolic syndrome population: An effectiveness and cost-effectiveness analysis
by: Zomer, E., et al.
Published: (2013)

Pharmacogenetics in cardiovascular disorders: An update on the principal drugs
by: Predazzi, I., et al.
Published: (2013)

COST-EFFECTIVENESS OF RENAL DENERVATION THERAPY FOR TREATMENT RESISTANT HYPERTENSION: A BEST CASE SCENARIO
by: Chowdhury, E., et al.
Published: (2018)

Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension: A best case scenario
by: Chowdhury, E., et al.
Published: (2018)

Clinical outcomes in patients with stable coronary artery disease with vs. without a history of myocardial revascularization
by: Elbez, Y., et al.
Published: (2016)

A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk
by: Patel, A., et al.
Published: (2015)

DEVELOPMENT OF A CARDIOVASCULAR MORTALITY RISK PREDICTION MODEL FOR PARTICIPANTS IN THE OHASAMA STUDY
by: Huq, M., et al.
Published: (2014)

Applying a framework to assess the impact of cardiovascular outcomes improvement research
by: Sarkies, Mitchell, et al.
Published: (2021)

Cost–Utility of Angiotensin-Converting Enzyme Inhibitor-Based Treatment Compared With Thiazide Diuretic-Based Treatment for Hypertension in Elderly Australians Considering Diabetes as Comorbidity
by: Chowdhury, E., et al.
Published: (2015)

More or less physical activity and the effect on cardiovascular mortality in a high-risk population
by: Zomer, E., et al.
Published: (2011)

Endovascular Stents and Stent Grafts in the Treatment of Cardiovascular Disease
by: Sun, Zhonghua
Published: (2014)

Population screening an important step in identifying and increasing awareness of cardiovascular disease in developing countries
by: Davidson, P., et al.
Published: (2012)

Assessment of vitamin D and its association with cardiovascular disease risk factors in an adult migrant population: An audit of patient records at a Community Health Centre in Kensington, Melbourne, Australia
by: Ruwanpathirana, T., et al.
Published: (2014)

Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease
by: Kalra, P., et al.
Published: (2017)

Can oral vitamin D prevent the cardiovascular diseases among migrants in Australia? Provider perspective using Markov modelling
by: Ruwanpathirana, T., et al.
Published: (2015)

COST-UTILITY ANALYSIS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR-BASED TREATMENT COMPARED TO THIAZIDE DIURETIC-BASED TREATMENT IN AN ELDERLY HYPERTENSIVE POPULATION CONSIDERING MAJOR COMORBIDITIES AT THE COMMUNITY LEVEL
by: Chowdhury, E., et al.
Published: (2014)